Clinical trial · no report yet · Phase 3
NCT05933577
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
- NCT05933577 ↗
- Active not recruiting
- Merck Sharp & Dohme LLC
- 36 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 25 | |
| Podcasts | 6 | |
| YouTube | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Melanoma
- Interventions
- Intismeran autogene; Pembrolizumab; Placebo
- Arms
- Intismeran autogene + Pembrolizumab · Experimental
- Placebo + Pembrolizumab · Active comparator
- Enrollment
- 1,089 (estimated)
- Primary outcomes
- Recurrence-Free Survival (RFS)
- Sponsor
- Merck Sharp & Dohme LLC with ModernaTX, Inc.
- Start
- Jul 19, 2023
- Primary completion
- Oct 26, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT05933577 · updated Sep 24, 2025